Tevogen Bio Inc. Confirms elimination of liabilities of US$94.9 million and reports US$11.3 million in net profit Informs that net cash used for operating activities was...
INVENTIVA Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9...
Genelux Corporation WESTLAKE VILLAGE, Calif., May 9, 2024 (GLOBE NEWSWIRE) – Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced Q1 2024 financial results...
eFFECTOR Therapeutics, Inc. Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross...
